Download Library

 
 
 
Download Library
Document Type
Articles of Association dated May 16, 2017
pdf
330.5 KB
Phase Ib/II atezolizumab with or without daratumumab in previously treated advanced or metastatic NSCLC - ASCO abstract - May 2017 (Pillai)
PDF
81.7 KB
Daratumumab in combination with KRd in patients with newly diagnosed multiple myeloma (MMY1001) - ASCO presentation - June 2017 (Jakubowiak)
PDF
83.7 KB
Efficacy of DRd or DVd in RRMM based on cytogenetic risk status - ASCO abstract - May 2017 (Weisel)
PDF
97.0 KB
DRd vs Rd in RRMM: Efficacy and safety update (POLLUX) -ASCO abstract - May 2017 (Bahlis)
PDF
89.7 KB
Safety and efficacy of daratumumab-based regimens in elderly patients with RRMM: Subgroup analysis of POLLUX and CASTOR - ASCO abstract - May 2017 (Mateos)
PDF
150.8 KB
DVd vs Vd in RRMM: Efficacy and safety update (CASTOR) - ASCO abstract - May 2017 (Lentzsch)
PDF
87.3 KB
Development of a clinical trial immunohistochemistry assay using a novel antibody to CD38 - ASCO abstract - May 2017 (Wakamiya)
PDF
31.3 KB
Interim Report for the First Quarter 2017
pdf
535.0 KB
Genmab Q1 2017 Results Presentation
PDF
250.9 KB
Q1 2017 Results Podcast
MP3
22.2 MB
Election Results of the Annual General Meeting 2017
PDF
91.4 KB
Scientific Committee Charter
PDF
155.3 KB
AGM 2017 Presentation
PDF
1.4 MB
Genmab 2016 Annual Report
pdf
8.7 MB
Full Year 2016 Results Presentation
PDF
488.8 KB
Corporate Governance Report 2016 - English
PDF
332.4 KB
CSR Report 2016
PDF
274.2 KB
Investor Fact Sheet
PDF
1.7 MB
Full Year 2016 Results Podcast
MP3
28.2 MB
35th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US - January 2017
PDF
1.2 MB
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
PDF
470.6 KB
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
PDF
545.4 KB
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
PDF
3.3 MB

Page:
1
2
3
4
5
...
17
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Selskabsvedtægter dateret den. 16. maj 2017
pdf
306.5 KB
Safety and efficacy of daratumumab-based regimens in elderly patients with RRMM: Subgroup analysis of POLLUX and CASTOR - ASCO abstract - May 2017 (Mateos)
PDF
150.8 KB
Resumé 2016
PDF
2.4 MB
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH poster - December 2016 (Kumar)
PDF
530.3 KB
Management of transaminase elevations associated with idelalisib - EHA poster regarding ofatumumab submitted by Gilead - June 2016 (Ghia)
PDF
1.5 MB
Præsentation for Nordnet 30. maj 2016
PDF
1.2 MB
Resumé 2015
PDF
2.6 MB
Selskabsvedtægter dateret den 26. marts 2015
PDF
195.3 KB
Resumé 2014
PDF
1.3 MB
Danish Shareholder Association Event Presentation - September 2014
PDF
822.1 KB
Ordinær generalforsamling 2014 præsentation
PDF
2.6 MB
2013 årsrapport
pdf
6.0 MB
Samfundsansvar (CSR) - Lovpligtig redegørelse for 2013
URL
N/A
Redegørelse for virksomhedsledelse 2013
URL
N/A
Genmab offentliggør resultat for de første ni måneder af 2013
pdf
588.3 KB
Genmab offentliggør resultat for første halvår 2013 og opjusterer forventningerne til 2013
pdf
812.1 KB
Genmab offentliggør resultat for første kvartal 2013
pdf
969.7 KB
Ordinær generalforsamling 2013 præsentation
PDF
1.1 MB
2012 årsrapport
pdf
5.7 MB
Samfundsansvar (CSR) - Lovpligtig redegørelse for 2012
URL
N/A
Redegørelse for virksomhedsledelse 2012
URL
N/A
Genmab offentliggør resultat for de første ni måneder af 2012 og opjusterer forventningerne til 2012
pdf
233.3 KB
Genmab offentliggør resultat for første halvår 2012 og opjusterer forventningerne til 2012
pdf
321.8 KB
Genmab offentliggør resultat for første kvartal 2012
pdf
231.7 KB
Overordnede retningslinjer for incitamentsordninger
PDF
79.0 KB
Page:
1
2
3
4
Next Last